Farideh Jalali-Najafabadi

Farideh Jalali-Najafabadi

Auto-generated profile, based on publicly available information

Farideh Jalali-Najafabadi

Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FJFarideh Jalali-Najafabadi
Farideh Jalali-Najafabadi
MSMichael Stadler
Michael Stadler
NDNick Dand
Nick Dand
DJDeepak Jadon
Deepak Jadon
MSMehreen Soomro
Mehreen Soomro
BGBSTOP Study Group
BSTOP Study Group
In view of the growth of clinical risk prediction models using genetic data, there is an increasing need for studies that use appropriate methods to select the optimum number of features from a large number of genetic variants with a high degree of redundancy between features due to linkage disequilibrium (LD). Filter feature selection methods based on information theoretic criteria, are well suited to this challenge and will identify a subset of the original variables that should result in more accurate prediction. However, data collected from cohort studies are often high-dimensional genetic data with potential confounders presenting challenges to feature selection and risk prediction machine learning models. Patients with psoriasis are at high risk of developing a chronic arthritis known as psoriatic arthritis (PsA). The prevalence of PsA in this patient group can be up to 30% and the identification of high risk patients represents an important clinical research which would allow early intervention and a reduction of disability. This also provides us with an ideal scenario for the development of clinical risk prediction models and an opportunity to explore the application of information theoretic criteria methods. In this study, we developed the feature selection and psoriatic arthritis (PsA) risk prediction models that were applied to a cross-sectional genetic dataset of 1462 PsA cases and 1132 cutaneous-only psoriasis (PsC) cases using 2-digit HLA alleles imputed using the SNP2HLA algorithm. We also developed stratification method to mitigate the impact of potential confounder features and illustrate that confounding features impact the feature selection. The mitigated dataset was used in training of seven supervised algorithms. 80% of data was randomly used for training of seven supervised machine learning methods using stratified nested cross validation and 20% was selected randomly as a holdout set for internal validation. The risk prediction models were then further validated in UK Biobank dataset containing data on 1187 participants and a set of features overlapping with the training dataset.Performance of these methods has been evaluated using the area under the curve (AUC), accuracy, precision, recall, F1 score and decision curve analysis(net benefit). The best model is selected based on three criteria: the ‘lowest number of feature subset’ with the ‘maximal average AUC over the nested cross validation’ and good generalisability to the UK Biobank dataset. In the original dataset, with over 100 different bootstraps and seven feature selection (FS) methods, HLA_C_*06 was selected as the most informative genetic variant. When the dataset is mitigated the single most important genetic features based on rank was identified as HLA_B_*27 by the seven different feature selection methods, consistent with previous analyses of this data using regression based methods. However, the predictive accuracy of these single features in post mitigation was found to be moderate (AUC= 0.54 (internal cross validation), AUC=0.53 (internal hold out set), AUC=0.55(external data set)). Sequentially adding additional HLA features based on rank improved the performance of the Random Forest classification model where 20 2-digit features selected by Interaction Capping (ICAP) demonstrated (AUC= 0.61 (internal cross validation), AUC=0.57 (internal hold out set), AUC=0.58 (external dataset)). The stratification method for mitigation of confounding features and filter information theoretic feature selection can be applied to a high dimensional dataset with the potential confounders.

1 September 2021 in Biomedical Signal Processing and Control
Verified
Journal Article
Closed access
FJFarideh Jalali-Najafabadi
Farideh Jalali-Najafabadi
Chaitanya GadepalliChaitanya Gadepalli
Chaitanya Gadepalli
DJDelaram Jarchi
Delaram Jarchi
BCBarry M.G. Cheetham
Barry M.G. Cheetham

11 October 2024 in Heart
Verified
Journal Article
Open access
PDF file
CHCatriona Harrison
Catriona Harrison
SFSimon Frain
Simon Frain
FJFarideh Jalalinajafabadi
Farideh Jalalinajafabadi
SWSimon G. Williams
Simon G. Williams
BKBernard Keavney
Bernard Keavney
Background Studies predating widespread COVID-19 vaccination identified patients with congenital heart disease (CHD) as a group at increased risk of severe outcomes from COVID-19. Here we evaluate the impact of vaccination on COVID-19 outcomes among patients with CHD. Methods We conducted a case-control study using linked English electronic health records (n=3 18 135). Patients with CHD were matched with controls by age, sex, ethnicity and GP practice. The ‘prevaccination’ cohort comprised unvaccinated patients with CHD and matched controls with first-recorded SARS-CoV-2 infection between 1 March and 8 December 2020 (7805 cases, 27 620 controls). The ‘post-vaccination’ cohort comprised vaccinated patients with CHD and matched controls with first-recorded SARS-CoV-2 infection between 1 March 2021 and 1 April 2022, at least 14 days after vaccination (57 550 cases, 225 160 controls). Odds of severe COVID-19 outcomes were compared using conditional logistic regression. We also compared the rate at which vaccine efficacy diminished, and the incidence of vaccine-associated complications. Results Compared with the prevaccination cohort, postvaccination patients with CHD exhibited markedly reduced rates of COVID-19-related hospitalisation (0.5% vs 15.8%) and mortality rates (0.5% vs 4.6%). Compared with vaccinated controls, vaccinated patients with CHD remained at increased risk of hospitalisation (0.5% vs 0.2%, adjusted OR 2.24 (1.88–2.65); p<0.001) and death (0.5% vs 0.3%, adjusted OR 1.81 (1.54–2.13); p<0.001). There was no evidence that vaccine efficacy declined faster in patients with CHD, or that patients with CHD experienced a larger increase in incidence of myocarditis, pericarditis or thrombotic events. Conclusion We observed a lower absolute risk of hospitalisation and death from COVID-19 in CHD patients after vaccination. However, in vaccinated CHD patients, an elevated risk of severe outcomes persists compared with vaccinated people without CHD. These results emphasise the importance of vaccination in the CHD population, and of vigilance among care providers dealing with COVID-19 infection in CHD patients, even if fully vaccinated.

1 November 2013
Verified
Conference Paper
Closed access
FJFarideh Jalalinajafabadi
Farideh Jalalinajafabadi
Chaitanya GadepalliChaitanya Gadepalli
Chaitanya Gadepalli
FAFrances Ascott
Frances Ascott
JHJarrod Homer
Jarrod Homer
MLMikel Lujan
Mikel Lujan
BCBarry Cheetham
Barry Cheetham
The GRBAS scale is a widely used subjective measure of voice quality. The aim of this paper is to investigate the correlation between the 'grade', 'roughness', 'breathiness', 'asthenia' and 'strain' dimensions of this scale and the objective measurements provided by the 'Analysis of Dysphonia in speech and Voice' (ADSV) software package. To do this, voice recordings of 107 samples were collected in a quiet room, and each voice was perceptually evaluated on the GRBAS scale by three experienced speech and language therapists. The same recordings were also acoustically analysed using ADSV. Statistical analysis using the Spearman's rank correlation coefficient model identified a degree of moderate correlation between the result of cepstral based analysis and the GRBAS scale. A classifier such as a decision tree may then be applied to the ADSV cepstral measurement for the objective prediction of GRBAS scores. The accuracy of the classifier in predicting the score of each therapist is given in the paper.

19 June 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
FJFarideh Jalali-Najafabadi
Farideh Jalali-Najafabadi
RBRowena Bailey
Rowena Bailey
JLJane Lyons
Jane Lyons
AAAshley Akbari
Ashley Akbari
TDThamer Ba Dhafari
Thamer Ba Dhafari
NPNiels Peek
Niels Peek
Objectives To compare the patterns of multimorbidity between people with and without rheumatic and musculoskeletal diseases (RMDs) and to describe how these patterns change by age and sex over time, between 2010 and 2019. Participants 103 426 people with RMDs and 2.9 million comparators registered in 395 Wales general practices (GPs). Each patient with an RMD aged 0–100 years between January 2010 and December 2019 registered in Clinical Practice Research Welsh practices was matched with up to five comparators without an RMD, based on age, gender and GP code. Primary outcome measures The prevalence of 29 Elixhauser-defined comorbidities in people with RMDs and comparators categorised by age, gender and GP practices. Conditional logistic regression models were fitted to calculate differences (OR, 95% CI) in associations with comorbidities between cohorts. Results The most prevalent comorbidities were cardiovascular risk factors, hypertension and diabetes. Having an RMD diagnosis was associated with a significantly higher odds for many conditions including deficiency anaemia (OR 1.39, 95% CI (1.32 to 1.46)), hypothyroidism (OR 1.34, 95% CI (1.19 to 1.50)), pulmonary circulation disorders (OR 1.39, 95% CI 1.12 to 1.73) diabetes (OR 1.17, 95% CI (1.11 to 1.23)) and fluid and electrolyte disorders (OR 1.27, 95% CI (1.17 to 1.38)). RMDs have a higher proportion of multimorbidity (two or more conditions in addition to the RMD) compared with non-RMD group (81% and 73%, respectively in 2019) and the mean number of comorbidities was higher in women from the age of 25 and 50 in men than in non-RMDs group. Conclusion People with RMDs are approximately 1.5 times as likely to have multimorbidity as the general population and provide a high-risk group for targeted intervention studies. The individuals with RMDs experience a greater load of coexisting health conditions, which tend to manifest at earlier ages. This phenomenon is particularly pronounced among women. Additionally, there is an under-reporting of comorbidities in individuals with RMDs.